IP Library Granted Patent US 12,611,548
Granted Patent B2
US 12,611,548 · App. 17/771,566 · Granted Apr 28, 2026

Treatment apparatus, systems and methods

Inventors: Yaron Segal (Jerusalem, IL); Yael Djemal-Kay (Jerusalem, IL)
Assignee: BrainQ Technologies Ltd.
A61N2/02A61N2/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,611,548
App. No.
17/771,566
Granted
Apr 28, 2026
Kind
B2
Abstract

Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto, the apparatus including a coil mounting portion and a body mounting portion, the coil mounting portion being removably mounted on the body mounting portion and a system including at least one database storing information relating to treatment protocols, a server communicating with the at least one database and body wearable treatment apparatus communicating with the server, the body wearable treatment apparatus including a coil mounting portion and a body mounting portion, the coil mounting portion being removably mounted on the body mounting portion.

Claims (41)

1 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of a central nervous system by application of electromagnetic fields thereto, the apparatus comprising:

a coil mounting portion comprising a head surrounding portion positionable with respect to a head of a patient and extending to a back portion positionable with respect to a back of the patient, and including an electromagnetic field generating coil extending from the head surrounding portion down along a length of the back portion; and

a body mounting portion,

said coil mounting portion being removably mounted on said body mounting portion.

2 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 1 and wherein said coil mounting portion is selectably positionable relative to said body mounting portion.

3 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 1 and also comprising an electronic control unit.

4 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 3 and wherein said control unit provides at least one of the following functions:

communication with an external server which stores treatment protocols so as to download specific treatment protocols for a given patient at a given time;

wave generation functionality operative to control application of current to said electromagnetic field generating coil in accordance with said specific treatment protocols for said given patient at said given time; and

feedback functionality operative to provide feedback confirming progress of said specific treatment protocols.

5 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 3 and wherein said control unit provides at least two of the following functions:

communication with an external server which stores treatment protocols so as to download specific treatment protocols for a given patient at a given time;

wave generation functionality operative to control application of current to said electromagnetic field generating coil in accordance with said specific treatment protocols for said given patient at said given time; and

feedback functionality operative to provide feedback confirming progress of said specific treatment protocols.

6 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 3 and wherein said control unit provides all of the following functions:

communication with an external server which stores treatment protocols so as to download specific treatment protocols for a given patient at a given time;

wave generation functionality operative to control application of current to said electromagnetic field generating coil in accordance with said specific treatment protocols for said given patient at said given time; and

feedback functionality operative to provide feedback confirming progress of said specific treatment protocols.

7 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 1 and wherein said coil mounting portion comprises:

a coil support substrate, formed to define the head surrounding portion and the back portion; and

the electromagnetic field generating coil mounted onto said coil support substrate.

8 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 7 and wherein said electromagnetic field generating coil is a single coil, which is connected to an electronic control unit at opposite ends thereof.

9 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 7 and wherein said electromagnetic field generating coil is formed of a flat braided conductor.

10 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 7 and wherein said electromagnetic field generating coil is arranged in interconnected upper and lower electromagnetic field generating coil winding portions.

11 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 10 and wherein said upper electromagnetic field generating coil winding portion extends along said coil support substrate adjacent a top edge of said head surrounding portion and up and down along said length of said back portion at an interior thereof.

12 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 10 and wherein said lower electromagnetic field generating coil winding portion extends along said coil support substrate adjacent a bottom edge of said head surrounding portion thereof and up and down along a length of said back portion adjacent an edge thereof.

13 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 7 and wherein said electromagnetic field generating coil comprises multiple coil windings, which are retained in a mutually stacked orientation by connectors.

14 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 1 and wherein said body mounting portion comprises a flexible band with a narrowed portion formed at a rear portion thereof.

15 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 14 and wherein said coil mounting portion comprises a channel through which said flexible band extends, thereby providing selectable vertical positioning of said coil mounting portion onto said body mounting portion.

16 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 1 and wherein said body mounting portion comprises a shoulder strap.

17 . Body wearable treatment apparatus for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 16 and wherein said shoulder strap is configured to position said coil mounting portion relative to the patient.

18 . A system for treatment of neurological disorders and conditions of a central nervous system by application of electromagnetic fields thereto, the system comprising:

at least one database storing information relating to treatment protocols;

a server communicating with said at least one database; and

a body wearable treatment apparatus communicating with said server, said body wearable treatment apparatus comprising:

a coil mounting portion comprising a head surrounding portion positionable with respect to a head of a patient and extending to a back portion positionable with respect to a back of the patient, and including an electromagnetic field generating coil extending from the head surrounding portion down along a length of the back portion; and

a body mounting portion,

said coil mounting portion being removably mounted on said body mounting portion.

19 . A system for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 18 and also comprising sensors for sensing real time sensed patient parameters.

20 . A system for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 19 and wherein said sensors are mounted on removably wearable substrates.

21 . A system for treatment of neurological disorders and conditions of the central nervous system by application of electromagnetic fields thereto according to claim 20 and wherein said removably wearable substrates are selected from a helmet and a glove.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2022
From: SEGAL, YARON; DJEMAL-KAY, YAEL
To: BRAINQ TECHNOLOGIES LTD.
Reel/Frame 061453/0257 →
Continuity (3)
Provisional Application 63071599 · Aug 28, 2020
Provisional Application 62946754 · Dec 11, 2019
Related Publication 20220379133A1 · Dec 1, 2022
References Cited (181)
US 5195941A · Erickson · 1993 [cited by examiner]
US 5314401A · Tepper · 1994 [cited by examiner]
US 5478303A · Foley-Nolan · 1995 [cited by examiner]
US 6024691A · Tepper · 2000 [cited by examiner]
US 6443883B1 · Ostrow et al. · 2002 [cited by applicant]
US 6463328B1 · John · 2002 [cited by applicant]
US 9392956B2 · Luo et al. · 2016 [cited by applicant]
US 9694197B2 · Segal · 2017 [cited by applicant]
US 10322295B2 · Segal · 2019 [cited by applicant]
US 20040002635A1 · Hargrove et al. · 2004 [cited by applicant]
US 20050182287A1 · Becker · 2005 [cited by applicant]
US 20060122496A1 · George et al. · 2006 [cited by applicant]
US 20060129022A1 · Venza · 2006 [cited by examiner]
US 20080139871A1 · Muntermann · 2008 [cited by applicant]
US 20090099627A1 · Molnar et al. · 2009 [cited by applicant]
US 20090306491A1 · Haggers · 2009 [cited by applicant]
US 20100016651A1 · Sivo · 2010 [cited by applicant]
US 20100210894A1 · Pascual-leone et al. · 2010 [cited by applicant]
US 20110046432A1 · Simon et al. · 2011 [cited by applicant]
US 20110112427A1 · Phillips et al. · 2011 [cited by applicant]
US 20110190849A1 · Faltys et al. · 2011 [cited by applicant]
US 20110295350A1 · Mercanzini et al. · 2011 [cited by applicant]
US 20120238835A1 · Hyde et al. · 2012 [cited by applicant]
US 20120271375A1 · Wu et al. · 2012 [cited by applicant]
US 20130268016A1 · Xi et al. · 2013 [cited by applicant]
US 20140023999A1 · Greder · 2014 [cited by applicant]
US 20140148657A1 · Hendler et al. · 2014 [cited by applicant]
US 20140163304A1 · Burnett et al. · 2014 [cited by applicant]
US 20140179986A1 · Kelley · 2014 [cited by applicant]
US 20140200388A1 · Schneider et al. · 2014 [cited by applicant]
US 20140303425A1 · Pilla et al. · 2014 [cited by applicant]
US 20150018706A1 · Segal · 2015 [cited by applicant]
US 20150066104A1 · Wingeier et al. · 2015 [cited by applicant]
US 20150105837A1 · Aguilar Domingo · 2015 [cited by applicant]
US 20150112409A1 · Hagedorn · 2015 [cited by applicant]
US 20150133718A1 · Schneider et al. · 2015 [cited by applicant]
US 20150257700A1 · Fu · 2015 [cited by applicant]
US 20150375005A1 · Segal · 2015 [cited by applicant]
US 20160015995A1 · Leung · 2016 [cited by examiner]
US 20160136427A1 · De Ridder · 2016 [cited by applicant]
US 20160184599A1 · Segal · 2016 [cited by applicant]
US 20160213276A1 · Gadot et al. · 2016 [cited by applicant]
US 20160220836A1 · Parks · 2016 [cited by applicant]
US 20170165485A1 · Sullivan · 2017 [cited by examiner]
US 20170296837A1 · Jin · 2017 [cited by applicant]
US 20180043174A1 · Gurfein · 2018 [cited by applicant]
US 20180050216A9 · Burnett · 2018 [cited by applicant]
US 20180064950A1 · Segal · 2018 [cited by applicant]
US 20180214710A1 · Charles et al. · 2018 [cited by applicant]
US 20190209856A1 · Segal · 2019 [cited by applicant]
US 20190290925A1 · Gellman · 2019 [cited by examiner]
US 20190358465A1 · Segal · 2019 [cited by applicant]
US 20200001041A1 · Kranck · 2020 [cited by examiner]
US 20230372725A1 · Segal · 2023 [cited by applicant]
CN 1457905 · 2003 [cited by applicant]
CN 1879906 · 2006 [cited by applicant]
CN 103917156 · 2014 [cited by applicant]
CN 104902806A · 2015 [cited by applicant]
CN 107041750 · 2017 [cited by applicant]
CN 109906103 · 2019 [cited by applicant]
CN 110141780 · 2019 [cited by applicant]
CN 209253537 · 2019 [cited by applicant]
DE 202010005501 · 2010 [cited by examiner]
EP 2755550 · 2019 [cited by applicant]
JP 2007520290 · 2007 [cited by applicant]
JP 2014501582 · 2014 [cited by applicant]
JP 2014526336 · 2014 [cited by applicant]
KR 1020160007729 · 2016 [cited by applicant]
WO WO2004078260 · 2004 [cited by examiner]
WO 2011057028 · 2011 [cited by applicant]
WO 2013038400 · 2013 [cited by applicant]
WO 2015022679 · 2015 [cited by applicant]
WO 2015187712 · 2015 [cited by applicant]
WO 2016046830 · 2016 [cited by applicant]
WO 2018047164 · 2018 [cited by applicant]
WO WO2019161407 · 2019 [cited by applicant]
WO 2021117029 · 2021 [cited by applicant]
Notice of Reason(s) for Rejection Dated Jul. 23, 2024 From the Japan Patent Office Re. Application No. 2022-524662 and Its Translation Into English. (9 Pages). [cited by applicant]
Notice of Allowance dated Sep. 27, 2022, which issued during the prosecution of U.S. Appl. No. 16/441,614. [cited by applicant]
Notice of Allowance dated Oct. 21, 2022, which issued during the prosecution of Australian Patent Application No. 2017323663. [cited by applicant]
An Office Action together with an English Summary dated Aug. 29, 2022 which issued during the prosecution of Korean Patent Application No. 10-2019-7009744. [cited by applicant]
An Office Action together with an English Summary dated Oct. 17, 2022 which issued during the prosecution of Chinese Patent Application No. 10-2019-201780068350.3. [cited by applicant]
Notice of Allowance Dated Apr. 7, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/330,670. (7 pages). [cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Sep. 11, 2023 From the European Patent Office Re. Application No. 17848278.2. (4 Pages). [cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Apr. 3, 2023 From the European Patent Office Re. Application No. 20899302.2. (7 Pages). [cited by applicant]
U.S. Appl. No. 62/642,037, filed Mar. 13, 2018. [cited by applicant]
Xiong, Ye, Asim Mahmood, and Michael Chopp. “Neurorestorative treatments for .traumatic brain injury.” Discovery medicine 10.54 (2010): 434. [cited by applicant]
An International Search Report and a Written Opinion both dated Dec. 20, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050981. [cited by applicant]
U.S. Appl. No. 62/946,762, filed Dec. 11, 2019. [cited by applicant]
U.S. Appl. No. 62/946,754, filed Dec. 11, 2019. [cited by applicant]
An English translation of an Office Action dated Jan. 27, 2016 which issued during the prosecution of Chinese Patent Application No. 201280055647.3. [cited by applicant]
Niehaus, L., et al. “Abnormal postexcitatory and interhemispheric motor cortex .inhibition in writer's cramp.” Journal of neurology 248.1 (2001): 51-52. [cited by applicant]
Rosenbaum, R. Shayna, et al. “The case of KC: contributions of a memory-.impaired person to memory theory.” Neuropsychologia 43.7 (2005): 989-1021. [cited by applicant]
Emery, Gregory, et al. “Asymmetric Rab11 endosomes regulate delta recycling and specify cell fate in the [cited by applicant]
Khanna, Michael J. “The cognitive correlates of human brain oscillations.” Journal .of Neuroscience 26.6 (2006): 1669-1672. [cited by applicant]
Kernie, Steven G., Trent M. Erwin, and Luis F. Parada. “Brain remodeling due to neuronal and astrocytic proliferation after controlled cortical injury in mice.” .Journal of neuroscience research 66.3 (2001): 317-326. [cited by applicant]
U.S. Appl. No. 62/642,038, filed Mar. 13, 2018. [cited by applicant]
U.S. Appl. No. 61/533,917, filed Sep. 13, 2011. [cited by applicant]
European Search Report dated Mar. 17. 2015, which issued during the prosecution of Applicant's European App No. 12831890.4. [cited by applicant]
An International Search Report and a Written Opinion both dated Oct. 22. 2012, which issued during the prosecution of Applicant's PCT/IL2012/000255. [cited by applicant]
An International Preliminary Report on Patentability dated Mar. 12, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050981. [cited by applicant]
An English translation of an Office Action dated May 28, 2015 which issued during the prosecution of Chinese Patent Application No. 201280055647.3. [cited by applicant]
U.S. Appl. No. 62/747,671, filed Oct. 19, 2018. [cited by applicant]
An English translation of an Office Action dated May 31, 2016, which issued during the prosecution of Japanese Patent Application No. 2014-530377. [cited by applicant]
An English translation of an Office Action dated Mar. 7, 2017, which issued during the prosecution of Japanese Patent Application No. 2014-530377. [cited by applicant]
An Office Action dated Jun. 1. 2016, which issued during the prosecution of U.S. Appl. No. 14/344,606. [cited by applicant]
An Office Action dated Oct. 24, 2016, which issued during the prosecution of U.S. Appl. No. 14/344,606. [cited by applicant]
Nithianandasivam, Nartani. “Oligodendrocytes, Myelin and Multiple Sclerosis.” .(2018) University of Toronto Medical Journal 95.1. [cited by applicant]
An Office Action dated Jun. 29, 2018, which issued during the prosecution of U.S. Appl. No. 15/257,900. [cited by applicant]
Notice of Allowance dated Apr. 10, 2019, which issued during the prosecution of U.S. Appl. No. 15/257,900. [cited by applicant]
Notice of Allowance dated Feb. 28, 2019, which issued during the prosecution of U.S. Appl. No. 15/257,900. [cited by applicant]
Notice of Allowance dated Mar. 20, 2017, which issued during the prosecution of U.S. Appl. No. 14/344,606. [cited by applicant]
Notice of Allowance dated Apr. 5, 2017, which issued during the prosecution of Australian Patent Application No. 2012310074. [cited by applicant]
An Office Action dated Apr. 15, 2016, which issued during the prosecution of Australian Patent Application No. 2012310074. [cited by applicant]
An Office Action dated Mar. 28, 2018, which issued during the prosecution of Canadian Patent Application No. 2,848,549. [cited by applicant]
An English Translation of an Office Action dated Oct. 19, 2017, which issued during the prosecution of Israel Patent Application No. 231486. (the relevant part only). [cited by applicant]
Mantovani, Lorenzo Giovanni, et al. “Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis.” Farmeconomia. Health economics and therapeutic pathways 18.2S (2017). [cited by applicant]
Maynard, Frederick M., et al. “International standards for neurological and functional classification of spinal cord injury.” Spinal cord 35.5 (1997): 266-274. [cited by applicant]
European Search Report dated Mar. 13, 2020, which issued during the prosecution of Applicant's European App No. 17848278.2. [cited by applicant]
An Office Action dated Feb. 17. 2020, which issued during the prosecution of Indian Patent Application No. 2133/DELNP/2014. [cited by applicant]
Elhalel, G., et al. “Cardioprotection from stress conditions by weak magnetic fields .in the Schumann Resonance band.” Scientific reports 9.1 (2019): 1-10. [cited by applicant]
Lee, Hae Ung, et al. “Subcellular electrical stimulation of neurons enhances the .myelination of axons by oligodendrocytes.” PloS one 12.7 (2017): e0179642. [cited by applicant]
An International Search Report and a Written Opinion both dated Mar. 26, 2021, which issued during the prosecution of Applicant's PCT/IL2020/051193. [cited by applicant]
An Office Action dated Dec. 4, 2020 which issued during the prosecution of Applicant's European App No. 17848278.2. [cited by applicant]
Cichon, Natalia, et al. “Increase in blood levels of growth factors involved in the neuroplasticity process by using an extremely low frequency electromagnetic field in post-stroke patients.” Frontiers in Aging Neurosci… [cited by applicant]
Cichoń, Natalia, et al. “Benign effect of extremely low-frequency electromagnetic field on brain plasticity assessed by nitric oxide metabolism during poststroke rehabilitation.” Oxidative Medicine and Cellular Longevit… [cited by applicant]
Ramos-Cejudo, Jaime, et al. “Traumatic brain injury and Alzheimer's disease: the .cerebrovascular link.” EBioMedicine 28 (2018): 21-30. [cited by applicant]
Ross, Christina L., and Benjamin S. Harrison. “Effect of pulsed electromagnetic field on inflammatory pathway markers in RAW 264.7 murine macrophages.” .Journal of inflammation research 6 (2013): 45. [cited by applicant]
Shih, Yao-Hsiang, et al. “Hypertension accelerates Alzheimer's disease-related .pathologies in pigs and 3xTg mice.” Frontiers in aging neuroscience 10 (2018): 73. [cited by applicant]
Sorensen, Per Soelberg, and Morten Blinkenberg. “The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future .prospects.” Therapeutic advances in neurological disorders 9.1 (20… [cited by applicant]
Zeilig, G., Gaidukov, E., Tavor, I., Livny, A., Alter, A., & Segal, Y. (2018). A Beneficial Effect Of A Brain Computer Interface Based Stimulation Device Aimed At Spinal Cord Injury Patients Impaired Neural Networks Imp… [cited by applicant]
Wang, Shiqian, et al. “Design and control of the MINDWALKER exoskeleton.” IEEE transactions on neural systems and rehabilitation engineering 23.2 (2014): .277-286. [cited by applicant]
Yakir-Blumkin, M. Ben, et al. “Neuroprotective Effect of Weak Static Magnetic Fields in Primary Neuronal Cultures.” .Neuroscience 278 (2014): 313-326. [cited by applicant]
An Office Action dated Aug. 17, 2021, which issued during the prosecution of U.S. Appl. No. 16/330,670. [cited by applicant]
Fotiou, D. F., et al. “Cholinergic deficiency in Alzheimer's and Parkinson's disease: Evaluation with pupillometry.” International Journal of Psychophysiology .73 (2009): 143-149. [cited by applicant]
Gamito, Pedro, et al. “Cognitive training on stroke patients via virtual reality-based .serious games.” Disability and rehabilitation 39.4 (2017): 385-388. [cited by applicant]
Westerberg, H., et al. “Computerized working memory training after stroke—.A pilot study.” Brain Injury 21.1 (2007): 21-29. [cited by applicant]
Gravanis, Iordanis, and Stella E. Tsirka. “tPA as a therapeutic target in stroke.” .(2008) Expert opinion on therapeutic targets 12.2. [cited by applicant]
Kirshblum, Steven C., et al. “International standards for neurological classification of spinal cord injury (Revised 2011).” The Journal of Spinal Cord Medicine 34.6 .(2011): 535. [cited by applicant]
An Office Action dated Feb. 3, 2022, which issued during the prosecution of U.S. Appl. No. 16/330,670. [cited by applicant]
An Office Action dated Mar. 25, 2022, which issued during the prosecution of U.S. Appl. No. 16/330,670. [cited by applicant]
An English translation of an Office Action dated Jul. 6, 2021, which issued during the prosecution of Japanese Patent Application No. 2019-533724. [cited by applicant]
An English translation of an Office Action dated Mar. 29, 2022, which issued during the prosecution of Japanese Patent Application No. 2019-533724. [cited by applicant]
An Office Action dated Mar. 29, 2022, which issued during the prosecution of U.S. Appl. No. 16/441,614. [cited by applicant]
Malone, Misti, et al. “Neuronal activity promotes myelination via a cAMP .pathway.” Glia 61.6 (2013): 843-854—Abstract. [cited by applicant]
Hojati, Zohreh, Maryam Kay, and Fariba Dehghanian. “Mechanism of action of interferon beta in treatment of multiple sclerosis.” Multiple sclerosis. Academic Press, 2016. 365-392—Abstract accessed on Aug. 28, 2022 {.http… [cited by applicant]
Johnson, Jon W., and Shawn E. Kotermanski. “Mechanism of action of memantine.” Current opinion in pharmacology 6.1 (2006): 61-67 Abstract accessed on Aug. 28, 2022 {https://www.sciencedirect.com/science/article/abs/pii/… [cited by applicant]
Langhorne, Peter, Robert Wagenaar, and Cecily Partridge. “Physiotherapy after stroke: more is better?.” Physiotherapy Research International 1.2 (1996): 75-88—Abstract accessed on Aug. 28, 2022 {https://onlinelibrary.wi… [cited by applicant]
Confavreux, Christian, and Sandra Vukusic. “The clinical course of multiple sclerosis.” Handbook of clinical neurology 122 (2014): 343-36988—Abstract accessed on Aug. 28, 2022 {https://www.sciencedirect.com/science/arti… [cited by applicant]
An International Preliminary Report on Patentability dated May 17, 2022, which issued during the prosecution of Applicant's PCT/IL2020/051193. [cited by applicant]
Grassi, Guido, et al. “Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials.” Current Hypertension Reports 4.9 (2007): 299-304—Abstract accessed on Aug. 28, 2022 {https://www.infon… [cited by applicant]
An Office Action dated Oct. 20, 2021, which issued during the prosecution of Australian Patent Application No. 2017323663. [cited by applicant]
An Office Action dated Jul. 27, 2021, which issued during the prosecution of Indian Patent Application No. 201917013336. [cited by applicant]
Rudick, Richard A., and Susan E. Goelz. “Beta-interferon for multiple sclerosis.” .Experimental cell research 317.9 (2011): 1301-1311—Abstract. [cited by applicant]
Seltzer, Ben. “Donepezil: a review.” Expert opinion on drug metabolism & toxicology 1.3 (2005): 527-536—Abstract accessed on Aug. 28, 2022 .{https://www.tandfonline.com/doi/abs/10.1517/17425255.1.3.527}. [cited by applicant]
U.S. Appl. No. 63/079,496, filed Sep. 17, 2020. [cited by applicant]
U.S. Appl. No. 63/183,112, filed May 3, 2021. [cited by applicant]
U.S. Appl. No. 63/071,599, filed Aug. 28, 2020. [cited by applicant]
Requisition by the Examiner Dated Oct. 16, 2023 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,034,752. (5 Pages). [cited by applicant]
English Summary Dated May 15, 2023 of Notification of Office Action Dated May 6, 2023 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3. (2 pages). [cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Jun. 13, 2025 From the European Patent Office Re. Application No. 20899302.2 (9 Pages). [cited by applicant]
Decision on Rejection Dated Jul. 27, 2023 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3. (5 Pages). [cited by applicant]
Hearing Notice Dated Jan. 11, 2024 From the Government of India, Intellectual Property India, The Patent Office Re. Application No. 201917013336. (2 Pages). [cited by applicant]
Hearing Notice Dated Jan. 12, 2024 From the Government of India, Intellectual Property India, The Patent Office Re. Application No. 2133/DELNP/2014. (4 Pages). [cited by applicant]
Notice of Reason for Rejection Dated Mar. 7, 2017 From the Japan Patent Office Re. Application No. 2014-530377. (4 Pages). [cited by applicant]
Notice of Reason for Rejection Dated May 23, 2016 From the Japan Patent Office Re. Application No. 2014-530377. (4 Pages). [cited by applicant]
Notification of Decision of Grant Dated Oct. 17, 2017 From the Japan Patent Office Re. Application No. 2014-530377. (3 Pages). [cited by applicant]
English Summary Dated Aug. 8, 2023 of Decision on Rejection Dated Jul. 27, 2023 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3. (3 pages). [cited by applicant]
Machine Translation Dated Aug. 14, 2023 of Decision on Rejection Dated Jul. 27, 2023 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3. (5 pages). [cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Jul. 25, 2017 From the European Patent Office Re. Application No. 12831890.4 (3 Pages). [cited by applicant]
Grounds of Reason of Rejection Dated Dec. 19, 2018 From the Korean Intellectual Property Office Re. Application No. 10-2001897 (6 pages). [cited by applicant]
International Preliminary Report on Patentability Dated Mar. 18, 2014 From the International Bureau of WIPO Re. Application No. PCT/IL2012/000255. (5 Pages). [cited by applicant]
Notification of Office Action and Search Report Dated Oct. 17, 2022 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3 and its Summary in English. (10 Pages). [cited by applicant]
Notification of Office Action Dated Jan. 27, 2016 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201280055647.3 (3 pages). [cited by applicant]
Notification of Office Action Dated May 28, 2015 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201280055647.3. (4 pages). [cited by applicant]
Translation of Notification of Office Action and Search Report Dated Oct. 17, 2022 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3. (6 Pages). [cited by applicant]
Notification of Office Action Dated May 6, 2023 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780068350.3. (5 Pages). [cited by applicant]
Examination Report Dated Aug. 11, 2025 From the Australian Government, IP Australia Re. Application No. 2020399308. (5 Pages). [cited by applicant]
Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 Dated Sep. 24, 2025 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical I… [cited by applicant]
Notification of Office Action and Search Report Dated Oct. 28, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080073123.1 with Its Summary and Machine Translati… [cited by applicant]
Requisition by the Examiner Dated Nov. 13, 2025 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 3,152,608. (6 Pages). [cited by applicant]